Shero,
As I said in my previous post, I was simply reading through what is claimed to be the abstract of the ASCO presentation posted by GregSL right here on SI. See the BOLD section for what I am referring to.
Greg's post:
Message 9559483
----------------- posted again below for convenience --------------
"Absract of the ASCO presentation, courtesy of Reviewer1 on Yahoo.
Phase I Results of Intra-Tumoral Infusion of I-131 ch-TNT-1/B in the Treatment of Recurrent Malignant Gliomas. Sunil J. Patel, Ken Spicer, Pamela VanTassel, Stephen Haines, Leonnie Gordon, Art Frankel, Jamie Oliver. Techniclone Corporation, Tustin, CA.
TNT-1/B is an iodine-131 complexed chimeric antibody targeted to the DNA/histone complex. The antibody binds to exposed antigen and delivers a collateral ionizing radiation to surrounding tumor cells. Nine patients with recurrent glioblastoma multiforme and 3 with recurrent anaplastic astrocytoma were enrolled in a dose-escalating phase I study using intra-tumoraly administered TNT-1/B. Study drug was infused over 24 hours. Six patients received fixed doses of TNT-1/B and were given both imaging and therapeutic doses to assess radiation dosimetry and biodistribution. The remaining six patients were treated with single individualized doses estimated to deliver 15,000 (N=4) or 22,500 cGy (N=2) to the gadolinium enhancing tumor volume (GETV). GETV ranged from 27-180 cc. all patients were treated with steroids both pre- and post-therapy. No patient received tumor debulking prior to TNT-1/B therapy. Radiation dosimetry from the first six patients estimated doses of radiation from 700-13000 cGy to the tumor with doses of 20-40 mCi of the drug. Initial estimates also indicated 34 (+/-9)% dose retention at 24 hours with an effective half-life of 45.5 (+/-15)hours. Non-target organ doses of radiation were well below toxicity levels. One case of thrombocytopenia at 30 days. To date 6 of 9 patients had stabilization of the tumor at 60 days follow-up. SPECT/MR image merging indicated drug distribution targeted to GETV. Median survival and time to progression have not yet been reached. 11 of 12 patients are alive. Longest survivor is at 8 months with a pontine glioblastoma.
Complete results and further follow-up will be p "
-------------------------------------------------------
So there you have it. That is my only source so far. The abstracts from ASCO should be released to the public tomorrow for confirmation.
conference-cast.com
Tarken |
